000 | 01905 a2200529 4500 | ||
---|---|---|---|
005 | 20250517210127.0 | ||
264 | 0 | _c20180604 | |
008 | 201806s 0 0 eng d | ||
022 | _a1573-2568 | ||
024 | 7 |
_a10.1007/s10620-018-5043-2 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aCaldera, Freddy | |
245 | 0 | 0 |
_aLower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients. _h[electronic resource] |
260 |
_bDigestive diseases and sciences _c06 2018 |
||
300 |
_a1532-1540 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntibodies, Bacterial _xblood |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 |
_aBordetella pertussis _ximmunology |
650 | 0 | 4 | _aCase-Control Studies |
650 | 0 | 4 | _aCross-Sectional Studies |
650 | 0 | 4 |
_aDiphtheria _ximmunology |
650 | 0 | 4 |
_aDiphtheria-Tetanus-acellular Pertussis Vaccines _xadministration & dosage |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunization, Secondary |
650 | 0 | 4 | _aImmunocompromised Host |
650 | 0 | 4 | _aImmunogenicity, Vaccine |
650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
650 | 0 | 4 |
_aInflammatory Bowel Diseases _xdiagnosis |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aSaha, Sumona | |
700 | 1 | _aWald, Arnold | |
700 | 1 | _aGarmoe, Christine A | |
700 | 1 | _aMcCrone, Sue | |
700 | 1 | _aMegna, Bryant | |
700 | 1 | _aLey, Dana | |
700 | 1 | _aReichelderfer, Mark | |
700 | 1 | _aHayney, Mary S | |
773 | 0 |
_tDigestive diseases and sciences _gvol. 63 _gno. 6 _gp. 1532-1540 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10620-018-5043-2 _zAvailable from publisher's website |
999 |
_c28229611 _d28229611 |